Acro Biomedical (ACBM) Gross Margin (2017 - 2022)

Acro Biomedical's Gross Margin history runs 6 years deep, the most recent figure standing at 17.78% for Q4 2022.

• In Q4 2022, Gross Margin fell 731.0% year-over-year to 17.78%; the TTM figure through Sep 2023 stood at 17.78% (down 749.0% YoY), while the FY2022 annual figure was 21.34%, down 33.0% from the prior year.
• Gross Margin was 17.78% for Q4 2022 at Acro Biomedical, down from 25.63% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 29.65% in Q1 2021 to a low of 6.25% in Q4 2019.
• Historically, Gross Margin has averaged 16.81% across 5 years, with a median of 16.0% in 2021.
• The sharpest annual moves came in 2021 and 2022: Gross Margin surged 648 bps in 2021, then slumped 731 bps in 2022.
• A 5-year view of Gross Margin shows it stood at 10.0% in 2018, then sank by 38 bps to 6.25% in 2019, then surged by 271 bps to 23.17% in 2020, then advanced by 8 bps to 25.08% in 2021, then fell by 29 bps to 17.78% in 2022.
• The last three Gross Margin figures came in at 17.78% (Q4 2022), 25.63% (Q1 2022), and 25.08% (Q4 2021), per Business Quant data.